Pralsetinib

Predictive

Supports Sensitivity Response

submitted

EID11870

Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC)

PMID 32284345 · Zhao et al., 2020 · Open in CIViC

RET E632_L633del2
Pralsetinib	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	2	submitted	EID12815 Ba/F3 cells transformed with E632_L633del showed IL-3 independent growth. Pralsetinib inhibited growth of the cells at IC50 14.9 +/- 1.8 nM. This was similar to the IC50 for selpercatinib, which the a… (full text at CIViC) PMID 37376747 · Szymczak et al., 2023 · Open in CIViC	civic
Pralsetinib + SelpercatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	2	submitted	EID12715 Wildtype or 632_633del RET was expressed in HEK293 cells, and MAPK reporter response assays were performed on these cells in triplicate, at various concentrations of inhibitors including selpercatinib… (full text at CIViC) PMID 36416226 · Wijewardene et al., 2023 · Open in CIViC	civic

RET E632_L633del2

Predictive

Supports Sensitivity Response

submitted

EID12815

Ba/F3 cells transformed with E632_L633del showed IL-3 independent growth. Pralsetinib inhibited growth of the cells at IC50 14.9 +/- 1.8 nM. This was similar to the IC50 for selpercatinib, which the a… (full text at CIViC)

PMID 37376747 · Szymczak et al., 2023 · Open in CIViC

Pralsetinib + SelpercatinibSubstitutes

Predictive

Supports Resistance

submitted

EID12715

Wildtype or 632_633del RET was expressed in HEK293 cells, and MAPK reporter response assays were performed on these cells in triplicate, at various concentrations of inhibitors including selpercatinib… (full text at CIViC)

PMID 36416226 · Wijewardene et al., 2023 · Open in CIViC

RET G810C1
Pralsetinib + SelpercatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	C	Supports Resistance	4	submitted	EID8918 Cell-free DNA was analysed in a patient with RET-mutant (M918T and V804M) medullary thyroid cancer and another patient with CCDC6-RET fusion positive non-small cell lung cancer who had developed acqui… (full text at CIViC) PMID 33161056 · Subbiah et al., 2021 · Open in CIViC	civic

RET G810C1

Pralsetinib + SelpercatinibSubstitutes

Predictive

Supports Resistance

submitted

EID8918

Cell-free DNA was analysed in a patient with RET-mutant (M918T and V804M) medullary thyroid cancer and another patient with CCDC6-RET fusion positive non-small cell lung cancer who had developed acqui… (full text at CIViC)

PMID 33161056 · Subbiah et al., 2021 · Open in CIViC

RET M918T1
Pralsetinib + SelpercatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	4	accepted	EID11867 Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC	civic

RET M918T1

Pralsetinib + SelpercatinibSubstitutes

Predictive

Supports Sensitivity Response

accepted

EID11867

PMID 32284345 · Zhao et al., 2020 · Open in CIViC

RET T930K1
Pralsetinib + SelpercatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID11869 Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC	civic

RET T930K1

Pralsetinib + SelpercatinibSubstitutes

Predictive

Supports Sensitivity Response

submitted

EID11869

PMID 32284345 · Zhao et al., 2020 · Open in CIViC

RET T930P1
Pralsetinib + SelpercatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Sensitivity Response	3	submitted	EID11868 Ba/F3 transformed cells harboring RET D898_E901del, T930K, T930P, or M918T mutations were shown to be sensitive to the highly selective RET inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667… (full text at CIViC) PMID 32284345 · Zhao et al., 2020 · Open in CIViC	civic

RET T930P1

Pralsetinib + SelpercatinibSubstitutes

Predictive

Supports Sensitivity Response

submitted

EID11868

PMID 32284345 · Zhao et al., 2020 · Open in CIViC

RET V738A1
Pralsetinib + SelpercatinibSubstitutes	Malignant NeoplasmALIAS	Predictive	D	Supports Resistance	3	submitted	EID8922 Cell line analyses using random mutation libraries identified four selpercatinib-resistant mutations and generation of selpercatinib-resistant cell lines by stepwise drug increase identified another R… (full text at CIViC) PMID 33161056 · Subbiah et al., 2021 · Open in CIViC	civic

RET V738A1

Pralsetinib + SelpercatinibSubstitutes

Predictive

Supports Resistance

submitted

EID8922

Cell line analyses using random mutation libraries identified four selpercatinib-resistant mutations and generation of selpercatinib-resistant cell lines by stepwise drug increase identified another R… (full text at CIViC)

PMID 33161056 · Subbiah et al., 2021 · Open in CIViC

RET Mutation + RET Fusion1
Pralsetinib	Malignant Thyroid Gland Neoplasm	Predictive	A	Supports Sensitivity Response	4	submitted	EID11267 In this multi-cohort, open-label, phase 1/2 study, 122 patients with RET-mutant medullary and 20 with RET fusion-positive thyroid cancers were started on pralsetinib dosed at 400 mg once daily. Overal… (full text at CIViC) PMID 34118198 · Subbiah et al., 2021 · Open in CIViC	civic

RET Mutation + RET Fusion1

Malignant Thyroid Gland Neoplasm

Predictive

Supports Sensitivity Response

submitted

EID11267

In this multi-cohort, open-label, phase 1/2 study, 122 patients with RET-mutant medullary and 20 with RET fusion-positive thyroid cancers were started on pralsetinib dosed at 400 mg once daily. Overal… (full text at CIViC)

PMID 34118198 · Subbiah et al., 2021 · Open in CIViC

RET Fusion1
Pralsetinib	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	3	submitted	EID11263 In the phase 1/2 clinical trial NCT03037385, one arm assessed the therapeutic benefit of the selective RET inhibitor pralsetinib across a range RET fusion positive solid tumors, excluding NSCLC and th… (full text at CIViC) PMID 35962206 · Subbiah et al., 2022 · Open in CIViC	civic

RET Fusion1

Solid NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID11263

In the phase 1/2 clinical trial NCT03037385, one arm assessed the therapeutic benefit of the selective RET inhibitor pralsetinib across a range RET fusion positive solid tumors, excluding NSCLC and th… (full text at CIViC)

PMID 35962206 · Subbiah et al., 2022 · Open in CIViC

RET Fusion1
Pralsetinib	Solid NeoplasmCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	submitted	EID11265 In the phase 1/2 clinical trial NCT03037385, one arm assessed the therapeutic benefit of the selective RET inhibitor pralsetinib across a range RET fusion positive solid tumors, excluding NSCLC and th… (full text at CIViC) PMID 35962206 · Subbiah et al., 2022 · Open in CIViC	civic

RET Fusion1

Solid NeoplasmCURATED_BROADER

Predictive

Supports Sensitivity Response

submitted

EID11265

PMID 35962206 · Subbiah et al., 2022 · Open in CIViC

RET G810S1
Pralsetinib + SelpercatinibSubstitutes	Thyroid Gland Medullary CarcinomaALIAS	Predictive	C	Supports Resistance	4	submitted	EID8919 Cell-free DNA was analysed in a patient with RET-mutant (M918T and V804M) medullary thyroid cancer and another patient with CCDC6-RET fusion positive non-small cell lung cancer who had developed acqui… (full text at CIViC) PMID 33161056 · Subbiah et al., 2021 · Open in CIViC	civic

RET G810S1

Pralsetinib + SelpercatinibSubstitutes

Thyroid Gland Medullary CarcinomaALIAS

Predictive

Supports Resistance

submitted

EID8919

PMID 33161056 · Subbiah et al., 2021 · Open in CIViC

RET Y806C1
Pralsetinib + SelpercatinibSubstitutes	Thyroid Gland Medullary CarcinomaALIAS	Predictive	C	Supports Resistance	3	submitted	EID8920 Cell-free DNA was analysed in a patient with RET-mutant (M918T and V804M) medullary thyroid cancer and another patient with CCDC6-RET fusion positive non-small cell lung cancer who had developed acqui… (full text at CIViC) PMID 33161056 · Subbiah et al., 2021 · Open in CIViC	civic

RET Y806C1

Pralsetinib + SelpercatinibSubstitutes

Thyroid Gland Medullary CarcinomaALIAS

Predictive

Supports Resistance

submitted

EID8920

PMID 33161056 · Subbiah et al., 2021 · Open in CIViC

RET Y806N1
Pralsetinib + SelpercatinibSubstitutes	Thyroid Gland Medullary CarcinomaALIAS	Predictive	C	Supports Resistance	3	submitted	EID8921 Cell-free DNA was analysed in a patient with RET-mutant (M918T and V804M) medullary thyroid cancer and another patient with CCDC6-RET fusion positive non-small cell lung cancer who had developed acqui… (full text at CIViC) PMID 33161056 · Subbiah et al., 2021 · Open in CIViC	civic

RET Y806N1

Pralsetinib + SelpercatinibSubstitutes

Thyroid Gland Medullary CarcinomaALIAS

Predictive

Supports Resistance

submitted

EID8921

PMID 33161056 · Subbiah et al., 2021 · Open in CIViC